Abstract
Previously, we developed a clinically relevant therapy model for advanced intracerebral B16 melanomas in syngeneic mice combining radiation and immunotherapies. Here, 7 days after B16-F10-luc2 melanoma cells were implanted intracerebrally (D7), syngeneic mice with bioluminescent tumors that had formed (1E105 to 7E106 photons per minute (>1E106, large; <1E106, small) were segregated into large-/small-balanced subgroups. Then, mice received either radiation therapy alone (RT) or radiation therapy plus immunotherapy (RT plus IT) (single injection of mAbPC61 to deplete regulatory T cells followed by multiple injections of irradiated granulocyte macrophage colony stimulating factor transfected B16-F10 cells) (RT plus IT). Radiation dose was varied (15, 18.75 or 22.5 Gy, given on D8), while immunotherapy was provided similarly to all mice. The data support the hypothesis that increasing radiation dose improves the outcome of immunotherapy in a subgroup of mice. The tumors that were greatly delayed in beginning their progressive growth were bioluminescent in vivo—some for many months, indicating prolonged tumor “dormancy,” in some cases presaging long-term cures. Mice bearing such tumors had far more likely received radiation plus immunotherapy, rather than RT alone. Radiotherapy is a very important adjunct to immunotherapy; the greater the tumor debulking by RT, the greater should be the benefit to tumor immunotherapy.
Similar content being viewed by others
Abbreviations
- Anti-PD-1:
-
Anti-programmed cell death protein 1 antibody
- C:
-
Control
- CNS:
-
Central nervous system
- D:
-
Day
- DAPI:
-
4′,6-Diamidino-2-phenylindole
- GM-CSF:
-
Granulocyte macrophage colony stimulating factor
- IL:
-
Interleukin
- ip:
-
Intraperitoneal
- IT:
-
Immunotherapy
- kVp:
-
Peak kilovoltage
- mAb:
-
Monoclonal antibody
- MCA:
-
Methylcholanthrene
- MHC:
-
Major histocompatibility complex
- NOD/SCID:
-
Non-obese diabetic/severe combined immunodeficiency
- NT:
-
No treatment
- RT:
-
Radiation therapy
- sc:
-
Subcutaneous
- Tregs:
-
Regulatory T cells
- TTP:
-
Time to tumor progression
References
Walbert T, Gilbert MR (2009) The role of chemotherapy in the treatment of patients with brain metastases from solid tumors. Int J Clin Oncol 14:299–306. doi:10.1007/s10147-009-0916-1
Langley RR, Fidler IJ (2013) The biology of brain metastasis. Clin Chem 59:180–189. doi:10.1373/clinchem.2012.193342
Smilowitz HM, Sasso D, Lee E, Goh G, Micca PL, Dilmanian FA (2013) Therapy model for advanced intracerebral B16 mouse melanoma using radiation therapy combined with immunotherapy. Cancer Immunol Immunother 62:1187–1197. doi:10.1007/s00262-013-1423-9
Prins RM, Soto H, Konkankit V, Odesa SK, Eskin A, Yong WH, Nelson SF, Liau LM (2011) Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res 17:1603–1615. doi:10.1158/1078-0432.CCR-10-2563
Phuphanich S, Wheeler CJ, Rudnick JD, Mazer M, Wang HQ, Nuno MA, Richardson JE, Fan X, Ji J, Chu RM, Bender JG, Hawkins ES, Patil CG, Black KL, Yu JS (2013) Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother 62:125–135. doi:10.1007/s00262-012-1319-0
Aguirre-Ghiso JA (2007) Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 7:834–846. doi:10.1038/nrc2256
Ossowski L, Aguirre-Ghiso JA (2009) Dormancy of metastatic melanoma. Pigment Cell Melanoma Res 23:41–56. doi:10.1111/j.1755-148X.2009.00647.x
Almog N (2010) Molecular mechanisms underlying tumor dormancy. Cancer Lett 294:139–146. doi:10.1016/j.canlet.2010.03.004
Barkan D, Green JE, Chambers AF (2010) Extracellular matrix: a gatekeeper in the transition from dormancy to metastatic growth. Eur J Cancer 46:1181–1188. doi:10.1016/j.ejca.2010.02.027
Bragado P, Sosa MS, Keely P, Condeelis J, Aguirre-Ghiso JA (2012) Microenvironments dictating tumor dormancy. Recent Results Cancer Res 195:25–39. doi:10.1007/978-3-642-28160-0_3
Rocken M (2010) Early tumor dissemination, but late metastasis: insights into tumor dormancy. J Clin Invest 120:1800–1803. doi:10.1172/JCI43424
Wells A, Griffith L, Wells JZ, Taylor DP (2013) The dormancy dilemma: quiescence versus balanced proliferation. Cancer Res 73:3811–3816. doi:10.1158/0008-5472.CAN-13-0356
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J, Gray R, Pierce L, Whelan T, Wang Y, Peto R (2011) Effect of radiotherapy after breast conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 378:1707–1716. doi:10.1016/S0140-6736(11)61629-2
Hensel JA, Flaig TW, Theodorescu D (2013) Clinical opportunities and challenges in targeting tumour dormancy. Nat Rev Clin Oncol 10:41–51. doi:10.1038/nrclinonc.2012.207
Mladenov E, Magin S, Soni A, Lliakis G (2013) DNA double-strand break repair as determinant of cellular radiosensitivity to killing and target in radiation therapy. Front Oncol 3:113. doi:10.3389/fonc.2013.00113
Burnette B, Weichselbaum RR (2013) Radiation as an immune modulator. Semin Radiat Oncol 23:273–280. doi:10.1016/j.semradonc.2013.05.009
Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, Smyth MJ, Schreiber RD (2007) Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450:903–907. doi:10.1038/nature06309
Liang H, Deng L, Chmura S, Burnette B, Liadis N, Darga T, Beckett MA, Lingen MW, Witt ME, Weichselbaum RR, Fu Y-X (2013) Radiation-induced equilibrium is a balance between tumor cell proliferation and T cell-mediated killing. J Immunol 190:5874–5881. doi:10.4049/jimmunol.1202612
Smilowitz HM, Slatkin DN, Lubimova N, Blattman H, Brauer-Krisch E, Bravin A, Di Michiel M, Stepanek J, Le Duc G, Gebbers J-O, Laissue JA (2006) Synergy of gene-mediated immunoprophylaxis and microbeam radiation therapy for advanced intracerebral rat 9L gliosarcomas. J Neurooncol 78:135–143. doi:10.1007/s11060-005-9094-9
Vatner RE, Cooper BT, Vanpouille-Box C, Demaria S, Fomenti SC (2014) Combinations of immunotherapy and radiation in cancer therapy. Front Oncol 4:325. doi:10.3389/fonc.2014.00325
Finkelstein SE, Timmerman R, McBride WH, Schaue D, Hoffe SE, Mantz CA, Wilson GD (2011) The confluence of stereotactic ablative radiotherapy and tumor immunology. Clin Dev Immunol 2011:439752. doi:10.1155/2011/439752
Chow KKH, Hara W, Lim M, Li G (2015) Combining immunotherapy with radiation for the treatment of glioblastoma. J Neurooncol 123:459–464. doi:10.1007/s11060-015-1762-9
Soukup K, Wang X (2015) Radiation meets immunotherapy—a perfect match in the era of combination therapy? Int J Rad Biol 91:299–305. doi:10.3109/09553002.2014.995383
Shahabi V, Postow MA, Tuck D, Wolchok JD (2015) Immune-priming of the tumor microenvironment by radiotherapy. Am J Clin Oncol 38:90–97. doi:10.1097/COC.0b013e3182868ec8
Wattenberg MM, Fahim A, Ahmed MM, Hodge JW (2014) Unlocking the combination: potentiation of radiation-induced antitumor responses with immunotherapy. Radiat Res 182:126–138. doi:10.1667/RR13374.1
Kershaw MH, Devaud C, John LB, Westwood JA, Darcy PK (2013) Enhancing immunotherapy using chemotherapy and radiation to modify the tumor microenvironment. Oncoimmunology 2:e25962. doi:10.4161/onci.25962
Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, Herati RS, Mansfield KD, Patsch D, Amaravadi RK, Schuchter LM, Ishwaran H, Mick R, Pryma DA, Xu X, Feldman MD, Gangadhar TC, Hahn SM, Wherry EJ, Vonderheide RH, Minn AJ (2015) Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520:373–377. doi:10.1038/nature14292
Filatenkov A, Baker J, Mueller AMS, Kenkel J, Ahn G-O, Dutt S, Zhang N, Kohrt H, Jensen K, Dejbakhsh-Jones S, Shizuru JA, Negrin RN, Engelman EG, Strober S (2015) Ablative tumor radiation can change the tumor immune cell microenvironment to induce durable complete remissions. Clin Cancer Res 21:3727–3739. doi:10.1158/1078-0432.CCR-14-2824
Persa E, Balogh A, Sáfrány G, Lumniczky K (2015) The effect of ionizing radiation on regulatory T cells in health and disease. Cancer Lett 368:252–261. doi:10.1016/j.canlet.2015.03.003
Sridharan V, Schoenfeld JD (2015) Immune effects of targeted radiation therapy for cancer. Discov Med 19:219–228
Gandhi SJ, Minn AJ, Vonderheide RH, Wherry EJ, Hahn SM, Maity A (2015) Awakening the immune system with radiation: optimal dose and fractionation. Cancer Lett 368:185–190. doi:10.1016/j.canlet.2015.03.024
Zeng J, Harris TJ, Lim M, Drake CG, Tran PT (2013) Immune modulation and stereotactic radiation: improving local and abscopal responses. Biomed Res Int 2013:658126. doi:10.1155/2013/658126
Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC, Demaria S (2009) Fractionated but not single dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 15:5379–5388. doi:10.1158/1078-0432.CCR-09-0265
Burnette B, Weichselbaum RR (2015) The immunobiology of ablative radiation. Semin Radiat Oncol 25:40–45. doi:10.1016/j.semradonc.2014.07.009
Mondini M, Nizard M, Tran T, Mauge L, Loi M, Clemenson C, Duque D, Maroun P, Louvet E, Adam J, Badoual C, Helley D, Dransart E, Johannes L, Vozenin MC, Perfettiini JL, Tartour E, Deutsch E (2015) Synergy of radiotherapy and a cancer vaccine for the treatment of HPV-associated head and neck cancer. Mol Cancer Ther 14:1336–1345. doi:10.1158/1535-7163.MCT-14-1015
Hainfeld JF, Slatkin DN, Smilowitz HM (2004) The use of gold nanoparticles to enhance radiotherapy in mice. Phys Med Biol 49:N309–N315. doi:10.1088/0031-9155/49/18/N03
Acknowledgments
This work was supported by a University of Connecticut Health Center seed grant to Henry M. Smilowitz.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest in any form with respect to this article.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Smilowitz, H.M., Micca, P.L., Sasso, D. et al. Increasing radiation dose improves immunotherapy outcome and prolongation of tumor dormancy in a subgroup of mice treated for advanced intracerebral melanoma. Cancer Immunol Immunother 65, 127–139 (2016). https://doi.org/10.1007/s00262-015-1772-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-015-1772-7